IVD China last week: Wantai, MGI, KingMed Diagnostics, Berry Genomics

Wantai and UNOPS Partner to Advance Global Tuberculosis Prevention and Control

In December 2024, the United Nations Office for Project Services (UNOPS) and Wantai officially signed a long-term supply agreement for TB-IGRA. After rigorous multi-dimensional evaluations, including product performance, ease of use, and stability, Wantai's TB-IGRA stood out among numerous competitors and successfully secured a spot in the procurement list.

MGI Tech's Market Value Surges by RMB 10.8 Billion in Two Weeks

On February 10, MGI Tech' stock price surged. By the market close in the afternoon, the stock had risen by 20% to RMB 66 per share, with a market capitalization of RMB 27.49 billion.

At the close of trading on February 7, BGI Genomics' stock price was RMB 55 per share. Notably, on January 27, the stock closed at just RMB 39.96 per share.

KingMed Diagnostics Integrates DeepSeek to Drive AI-Powered Diagnostics

On February 10, 2025, KingMed Diagnostics officially integrated with DeepSeek, completing the deployment of the DeepSeek-R1 model on the "Yu Jian Yi Yan" large model and its accompanying AI application, "Xiao Yu Yi."

Leveraging DeepSeek’s high performance and cost advantages, KingMed Diagnostics will continue to develop a technology and service ecosystem centered around large models. The company aims to build a multimodal, all-scenario AI agent for the medical testing industry, accelerating the intelligent transformation of medical testing services and enhancing both external services and internal operations.

Berry Genomics Secures CE Certification for Three Core Products

Recently, Berry Genomics successfully obtained EU CE certification for three independently developed core products: the Human Exome Sequencing Library Preparation Kit (Reversible Termination Sequencing), the Fetal Free DNA Library Preparation Kit (Reversible Termination Sequencing), and the Thalassemia Gene Detection Kit (Single-Molecule Sequencing).